46. Khan Z, Vijayakumar S, de la Torre TV, Rotolo S, Bafico A (2007) Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol 27: 7291–7301. 47. Mi K, Johnson GV (2007) Regulated proteolytic processing of LRP6 results in release of its intracellular domain. J Neurochem 101: 517–529. 48. Yamamoto H, Komekado H, Kikuchi A (2006) Caveolin is necessary for Wnt- 3a-dependent internalization of LRP6 and accumulation of beta-catenin. Dev Cell 11: 213–223. 49. Yamamoto H, Sakane H, Michiue T, Kikuchi A (2008) Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of beta- catenin signaling. Dev Cell 15: 37–48. 50. Binnerts ME, Kim KA, Bright JM, Patel SM, Tran K, et al. (2007) R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc Natl Acad Sci U S A 104: 14700–14705. 51. Mikels AJ, Nusse R (2006) Purified Wnt5a protein activates or inhibits beta- catenin-TCF signaling depending on receptor context. PLoS Biol 4: e115. 52. Roarty K, Serra R (2007) Wnt5a is required for proper mammary gland development and TGF-beta-mediated inhibition of ductal growth. Development 134: 3929–3939. 53. Bryja V, Andersson ER, Schambony A, Esner M, Bryjova L, et al. (2009) The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling in vivo. Mol Biol Cell 20: 924–936. 54. Hendrickx M, Leyns L (2008) Non-conventional Frizzled ligands and Wnt receptors. Dev Growth Differ 50: 229–243. 55. Paguirigan A, Beebe DJ, Alexander CM (2007) Simulating mouse mammary gland development: cell ageing and its relation to stem and progenitor activity. Cell Prolif 40: 106–124. 56. Taddei I, Deugnier MA, Faraldo MM, Petit V, Bouvard D, et al. (2008) Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol 10: 716–722. 57. Li N, Zhang Y, Naylor MJ, Schatzmann F, Maurer F, et al. (2005) Beta1 integrins regulate mammary gland proliferation and maintain the integrity of mammary alveoli. EMBO J 24: 1942–1953. 58. Pontier SM, Muller WJ (2009) Integrins in mammary-stem-cell biology and breast-cancer progression—a role in cancer stem cells? J Cell Sci 122: 207–214. 59. Ruzankina Y, Brown EJ (2007) Relationships between stem cell exhaustion, tumour suppression and ageing. Br J Cancer 97: 1189–1193. 60. Kim WY, Sharpless NE (2006) The regulation of INK4/ARF in cancer and aging. Cell 127: 265–275. 61. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, et al. (2006) Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443: 421–426. Lrp5 in Mammary Stem Cells 62. Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, et al. (2006) Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 443: 448–452. 63. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, et al. (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714–718. 64. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, et al. (2005) TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24: 2458–2471. 65. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al. (1998) p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death- inducing, and dominant-negative activities. Mol Cell 2: 305–316. 66. Laurikkala J, Mikkola ML, James M, Tummers M, Mills AA, et al. (2006) p63 regulates multiple signalling pathways required for ectodermal organogenesis and differentiation. Development 133: 1553–1563. 67. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, et al. (2001) p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A 98: 3156–3161. 68. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, et al. (2002) DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 1: 369–379. 69. Adams PD, Enders GH (2008) Wnt signaling and senescence: A tug of war in early neoplasia? Cancer Biol Ther 7(11): 1706–1711. 70. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, et al. (2004) Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 19: 2033–2040. 71. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, et al. (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25: 329–332. 72. Liu BY, Kim YC, Leatherberry V, Cowin P, Alexander CM (2003) Mammary gland development requires syndecan-1 to create a beta-catenin/TCF- responsive mammary epithelial subpopulation. Oncogene 22: 9243–9253. 73. Shibamoto S, Higano K, Takada R, Ito F, Takeichi M, et al. (1998) Cytoskeletal reorganization by soluble Wnt-3a protein signalling. Genes Cells 3: 659–670. 74. Lee YJ, Streuli CH (1999) Extracellular matrix selectively modulates the response of mammary epithelial cells to different soluble signaling ligands. J Biol Chem 274: 22401–22408. 75. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7): 34.1–34.12. 76. Kordon EC, Smith GH (1998) An entire functional mammary gland may comprise the progeny from a single cell. Development 125: 1921–1930. PLoS ONE | www.plosone.org 14 August 2009 | Volume 4 | Issue 8 | e6594